CoChat

Molecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatment

VanArsdale, Todd, Boshoff, Chris, Arndt, Kim T., Abraham, Robert T. · 2015 · Clinical Cancer Research

The DOI matches its Crossref record; 61 of the 65 references it cites were found in a registry or an index.

Abstract

Cancer cells bypass normal controls over mitotic cell-cycle progression to achieve a deregulated state of proliferation. The retinoblastoma tumor suppressor protein (pRb) governs a key cell-cycle checkpoint that normally prevents G1-phase cells from entering S-phase in the absence of appropriate mitogenic signals. Cancer cells frequently overcome pRb-dependent growth suppression via constitutive phosphorylation and inactivation of pRb function by cyclin-dependent kinase (CDK) 4 or CDK6 partnered with D-type cyclins. Three selective CDK4/6 inhibitors, palbociclib (Ibrance; Pfizer), ribociclib (Novartis), and abemaciclib (Lilly), are in various stages of development in a variety of pRb-positive tumor types, including breast cancer, melanoma, liposarcoma, and non-small cell lung cancer. The emerging, positive clinical data obtained to date finally validate the two decades-old hypothesis that the cyclin D-CDK4/6 pathway is a rational target for cancer therapy.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-14-0816

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Show all 61 references

Cited by

See all 427

Metadata

Authors
VanArsdale, T., Boshoff, C., Arndt, K. T., & Abraham, R. T.
Affiliations
Pfizer (United States) (US)
Venue
Clinical Cancer Research
Published
2015-06-30
Volume
21
Issue
13
Pages
2905-2910
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2096979580
Cited by
396
References
65
Citations by year
2026: 18 · 2025: 24 · 2024: 47 · 2023: 34 · 2022: 43 · 2021: 48 · 2020: 44 · 2019: 48 · 2018: 32 · 2017: 31 · 2016: 19 · 2015: 7
FWCI
5.25
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
CDK4/6 inhibitors, palbociclib, ribociclib, abemaciclib, retinoblastoma protein, retinoblastoma protein phosphorylation, G1 cell cycle checkpoint, breast cancer, melanoma, liposarcoma, non-small cell lung cancer, targeted cancer therapy
MeSH terms
Animals, Antineoplastic Agents, Humans, Neoplasms, Signal Transduction, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Cyclin D, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatment. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-0816
The paper
VanArsdale, T., Boshoff, C., Arndt, K. T., & Abraham, R. T. (2015). Molecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatment. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-0816

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.